Home › Trial NCT00010192
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
- Trial IDNCT00010192
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorNational Cancer Institute (NCI)
- Enrollment30
- Start date2000-12
- ConditionsB-cell Adult Acute Lymphoblastic Leukemia · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue · Nodal Marginal Zone B-cell Lymphoma · Noncontiguous Stage II Adult Burkitt Lymphoma · Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma · Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.